Clinical trials: Metastatic Colorectal Cancer, completed
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
Colorectal Cancer
An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
This purpose of this study is to evaluate nivolumab (BMS-936558) in combination with standard of care (SOC) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mCRC).
- Trial name
- CheckMate 9X8 (NCT03414983)
- Testing
- Nivolumab, Oxaliplatin, Leucovorin
- Where
- 49 sites in United States, Canada and 3 more
- Volunteers
- 196 people
- Sponsor
- Bristol-Myers Squibb
Colon Cancer, Rectal Cancer
Cellular Immune Augmentation in Colon and Rectal Cancer
While new treatments for metastatic and recurrent colorectal cancer have become available over the past several years, this disease remains incurable with a limited life expectancy from the time of diagnosis.
- Trial name
- NCT00257322
- Testing
- GM-CSF
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Liver Neoplasms
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
This study is an open label prospective trial of TheraSphere treatment for patients who have liver metastases who have failed or are intolerant to other systemic or liver directed therapies.
- Trial name
- NCT01177007
- Testing
- TheraSphere, Yttrium-90 glass Microspheres
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Metastatic Colorectal Cancer
Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer
This is a phase II, randomized, multi-center, open-label, parallel-group study to evaluate the progression-free survival during maintenance therapy. Eligible patients will be treated within a 12-week induction therapy.
- Trial name
- PanaMa (NCT01991873)
- Testing
- Maintenance Chemotherapy, Panitumumab (Within maintenance phase), mFOLFOX6 (Within re-induction phase)
- Where
- 2 sites in Germany
- Volunteers
- 387 people
- Sponsor
- AIO-Studien-gGmbH
Colorectal Cancer
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.
- Trial name
- NCT01490866
- Testing
- Axitinib, Bevacizumab, 5-Fluorouracil
- Where
- 12 sites in United States
- Volunteers
- 70 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies.
- Trial name
- HERKULES-3 (NCT05039177)
- Testing
- ERAS-007, Encorafenib, Cetuximab
- Where
- 14 sites in United States
- Volunteers
- 101 people
- Sponsor
- Erasca, Inc.
Colorectal Cancer
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
The addition of RAD001, an mTOR inhibitor, to irinotecan and anti-EGFR antibody cetuximab may increase efficacy for patients with metastatic colorectal cancer who progressed on prior chemotherapy.
- Trial name
- NCT00522665
- Testing
- Irinotecan, Cetuximab, RAD001
- Where
- 14 sites in United States
- Volunteers
- 41 people
- Sponsor
- Hoosier Cancer Research Network
Metastatic Colorectal Cancer
Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.
- Trial name
- ALTER0703 (NCT02332499)
- Testing
- Anlotinib
- Where
- 29 sites in China
- Volunteers
- 419 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colorectal Cancer, Metastatic Cancer
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
This is an open-label, single-center, single-arm phase II clinical trial evaluating the combination of pembrolizumab, binimetinib, and bevacizumab in patients with metastatic colorectal adenocarcinoma who have not responded to…
- Trial name
- NCT03475004
- Testing
- Pembrolizumab, Bevacizumab, Binimetinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Colorado, Denver
Colorectal Cancer, Metastatic Cancer
Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver
RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the safety of NV1020 in patients who have colon cancer that has spread to the liver and has not responded to…
- Trial name
- NCT00012155
- Testing
- NV1020
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Approximately 36 DLT-evaluable subjects will be enrolled in this study. The locations of the study will be in the United States, Australia, Europe and Switzerland.
- Trial name
- NCT03256344
- Testing
- Talimogene Laherparepvec, Atezolizumab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 36 people
- Sponsor
- Amgen
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Adenocarcinoma of Rectum
First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis
The FOLFIRINOX protocol seems a promising protocol as attack treatment of a rectum cancer, with an objective response rate of about 70 %.
- Trial name
- NCT01674309
- Testing
- FOLFORINOX
- Where
- 37 sites in France
- Volunteers
- 65 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Metastatic Colorectal Cancer
Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms
The purpose of this study is to assess FOLFIRI+aflibercept efficacy in patients with or without ACE polymorphisms in terms of Progression-free survival (PFS).
- Trial name
- POLAF (NCT02970916)
- Testing
- FOLFIRI+aflibercept
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Colorectal Neoplasms
Stivarga Regulatory Post-Marketing Surveillance Study in Korea
To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.
- Trial name
- StivargaPMS (NCT02106858)
- Testing
- Regorafenib (Stivarga,BAY73-4506)
- Where
- South Korea
- Volunteers
- 316 people
- Sponsor
- Bayer
Colon Cancer, Rectal Cancer
Clinical Trial in Patients With Metastatic Colorectal Cancer
The objective of this trial is to compare efficacy and safety of CoFactor and 5-fluorouracil (5-FU) versus leucovorin and 5-FU in treatment of metastatic colorectal cancer.
- Trial name
- NCT00235898
- Testing
- CoFactor, 5-FU, Leucovorin
- Where
- 30 sites in India, Poland and 3 more
- Volunteers
- 300 people
- Sponsor
- Mast Therapeutics, Inc.
Colorectal Cancer
1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT01417494
- Testing
- Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen), Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Non-small Cell Lung Cancer, Head and Neck Cancer
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03518554
- Testing
- JAB-3068
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Colorectal Cancer, Colorectal Tumors
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
- Conditions
- Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
- Trial name
- CheckMate 9N9 (NCT03377361)
- Testing
- Nivolumab, Trametinib, Ipilimumab
- Where
- 47 sites in United States, Argentina and 8 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.